Back to Atlas
APotentially durableResearch-only / high verification need
CMP-0121
Research
SSK1
Senolytic / β-gal prodrug
Targeted senescent-cell elimination in preclinical models
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Senolytic prodrug
- Primary mechanism
- SA-β-gal-activated gemcitabine prodrug releases cytotoxic cargo in senescent cells
- Primary market use
- Senolytic research
Pharmacology
- Molecular weight (Da)
- 788.62
- Oral bioavailability
- N/A; preclinical systemic/local prodrug
- Half-life
- 8 hours
- Route tags
- Route-dependent / verify
- Evidence level
- Preclinical
- Clinical status
- Research
- Value-for-money score
- 5 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Mechanistically elegant targeted prodrug; not clinically established